Navigation Links
Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
Date:4/22/2009

PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from animal studies of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in consolidation treatment for leukemia and of CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection in combination with biological agents for the treatment of colorectal cancer were presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR) in Denver, Colorado (Abstracts 4568 and 4578).

"Even as we progress through Phase 2 human clinical trials with both CPX-351 and CPX-1, our ongoing work in xenograft models of human cancer provides important additional direction regarding their potential place in current treatment paradigms," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "These studies, which further highlight the utility of maintaining synergistic molar ratios of chemotherapeutic agents through nano-scale delivery vehicles, also suggest strategies for enhancing clinical outcomes with CPX-351 in leukemia and CPX-1 in colorectal cancer."

In the first presentation, researchers reported that CPX-351 was superior to standard cytarabine:daunorubicin free-drug cocktail in ablating leukemic bone marrow cells in the CCRF-CEM human leukemia xenograft model. Additional data showed median survival was improved by consolidation treatment with either CPX-351 or free drug cocktail therapies but long-term survival (beyond 100 days) was achieved only with CPX-351 induction and consolidation therapy. Furthermore, it appeared that intermediate dosing frequencies (days 1 & 3 or days 1 & 5) for consolidation treatment with CPX-351 produced superior efficacy to a longer dosing frequency (days 1 & 7), with regard to both survival improvement and bone marrow drug accumulation. Recovery times of normal bone marrow cellularity following consolidation treatments were comparable among all three consolidation dosing schedules studied.

The second presentation examined the effects of combining CPX-1 with either bevacizumab (Avastin(R)) or cetuximab (Erbitux(R)), biological agents frequently used in combination with chemotherapy for treating metastatic colorectal cancer, in mice engrafted with human colon tumor cells. CPX-1 combined with bevacizumab significantly enhanced the efficacy observed in the LS174T colorectal xenograft model when compared to either drug used as a single agent. Furthermore, CPX-1 combined with cetuximab significantly enhanced the efficacy observed in the DLD-1 colorectal xenograft model when compared to either drug used as a single agent. In both experiments, the addition of the monoclonal antibody to CPX-1 enhanced or potentiated anti-tumor activity, suggesting that these combinations might augment the promising efficacy observed in prior studies of CPX-1 as monotherapy.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

List of abstracts:

AACR Abstract #4568: Tardi P, Harasym T, Dos Santos N, et. al. CPX-351, a liposome formulation containing a synergistic 5:1 molar ratio of cytarabine (Cyt) and daunorubicin (Daun), exhibitis improved efficacy against human leukemia xenografts when administered at intermediate frequency in consolidation treatment. Poster presented Tuesday, April 21, 2009 (Hall B-F, Poster Section 33, Poster Board 1).

AACR Abstract #4578: Tardi P, Harasym T, Bermudes D, et al. CPX-1, a liposome formulation containing a synergistic 1:1 molar ratio of irinotecan and floxuridine, exhibits increased efficacy in combination with either bevacizumab (BEV) or cetuximab (CET) in human colorectal cancer (CRC) solid tumor xenograft models. Poster presented Tuesday, April 21, 2009 (Hall B-F, Poster Section 33, Poster Board 11).

Avastin(R) is a registered trademark of Genentech Inc.

Erbitux(R) is a registered trademark of ImClone Systems Incorporated


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
3. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
4. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
5. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Ten outstanding teachers in the Greater Houston area ... will win a visit by a Houston Texans player, two tickets to a Texans ... years old can visit texanschecking.com/stars to nominate their favorite teacher with an essay of ...
(Date:8/16/2017)... Georgia (PRWEB) , ... August 16, 2017 , ... ... in Atlanta, opened their doors. They celebrate 30 years in business this year, ... create an up-to-date, inviting, tranquil space to serve their patients. , It ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... 2017 , ... A global leader in the treatment of clubfoot, CURE ... Indian states—bringing the country one step closer to eliminating clubfoot as a lifelong disability ... on track to enroll 10,000 children in the clubfoot treatment program in this year ...
(Date:8/16/2017)... ... ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has announced their ... a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their content will ... in 2018. Proceeds will be going to further health research. , Fusion Flix ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for ... of an IPO. The United States ... of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... staggering figure is the fact that Americans spent $42 billion on anxiety ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: